efavirenz

GPTKB entity

Statements (66)
Predicate Object
gptkbp:instance_of gptkb:immunotherapy
gptkbp:approves gptkb:1998
gptkb:FDA
adults
gptkbp:available_on generic drug
gptkbp:belongs_to non-nucleoside reverse transcriptase inhibitors
gptkbp:brand gptkb:Atripla
gptkb:Sustiva
Symfi
Symfi Lo
gptkbp:can_be_combined_with gptkb:tenofovir
gptkb:emtricitabine
gptkbp:chemical_formula C14 H9 Cl F3 NO2
gptkbp:class arylpropylamine derivatives
gptkbp:clinical_trial Phase II
Phase III
Phase I
gptkbp:composed_by gptkb:chemical_compound
gptkbp:contraindication pregnancy
certain antidepressants
certain anticonvulsants
gptkbp:developed_by gptkb:Bristol-Myers_Squibb
gptkbp:dosage_form gptkb:tablet
gptkb:capsule
oral tablet
600 mg once daily
gptkbp:drug_interactions may decrease levels of certain drugs
may increase levels of certain drugs
gptkbp:excretion urine
feces
https://www.w3.org/2000/01/rdf-schema#label efavirenz
gptkbp:interacts_with gptkb:St._John's_Wort
gptkb:rifampin
CYP450 inducers
gptkbp:invention gptkb:2013
gptkbp:is_monitored_by liver function tests
lipid levels
neuropsychiatric symptoms
gptkbp:lifespan 40 to 55 hours
about 40 to 55 hours
gptkbp:marketed_as many countries
gptkbp:mechanism_of_action non-nucleoside reverse transcriptase inhibitor
non-competitive inhibition of reverse transcriptase
gptkbp:metabolism liver
CYP2 B6
gptkbp:provides_guidance_on WHO guidelines
CDC guidelines
AIDS Clinical Trials Group guidelines
often combined with tenofovir and emtricitabine
gptkbp:research_focus long-term effects
combination therapies
drug resistance
gptkbp:route_of_administration oral
gptkbp:safety Category D
gptkbp:side_effect dizziness
nausea
liver toxicity
rash
insomnia
hyperlipidemia
neuropsychiatric symptoms
gptkbp:storage room temperature
gptkbp:used_for treatment of HIV
HIV treatment
gptkbp:bfsParent gptkb:Atripla
gptkbp:bfsLayer 5